Prostate Cancer Reports



Volume 3 Number 7
July 2015
Home > Prostate Cancer Reports > Volume 3, Year 2015 > Number 7, July

CONTENTS

Epidemiology, Aetiology and pathology
Diagnostic evaluation
Treatment



EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY


Metastasis

Cellular adhesion

Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, Coleman R, Nguyen H, Nelson PS, Corey E, Snyder LA, Vessella RL, Morrissey C, Lam HM.
Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.
PLoS One. 2015 Jun 19;10(6):e0130565. doi: 10.1371/journal.pone.0130565. eCollection 2015.
Article | PubMed abstract | Full-text PDF | Similar articles


Osteoclasts

Zalucha JL, Jung Y, Joseph J, Wang J, Berry JE, Shiozawa Y, Taichman RS.
The Role of Osteoclasts in Early Dissemination of Prostate Cancer Tumor Cells.
J Cancer Stem Cell Res. 2015;3. pii: e1005.
Article | PubMed abstract | Full-text PDF | Similar articles

DIAGNOSTIC EVALUATION


Genomic markers

Davis JW.
Use of genomic markers to risk stratify men with prostate cancer
.
Trends In Urology & Mens Health
, May/June 2015
Article | Journal abstract | Full-text PDF


'Decipher' genomic test
Clinical practice decisions


Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J.
Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.
BJU Int. 2015 Mar;115(3):419-29. doi: 10.1111/bju.12789. Epub 2014 Aug 11.
Article | PubMed abstract | Full-text PDF | Similar articles


Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger J.
Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.
Oncotarget. 2013 Apr;4(4):600-9.
Article | PubMed abstract | Full-text PDF | Similar articles


Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ.
Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.
Article | PubMed abstract | Full-text PDF | Similar articles


Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ.
Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
J Clin Oncol. 2015 Mar 10;33(8):944-51. doi: 10.1200/JCO.2014.59.0026. Epub 2015 Feb 9. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416.
Article | PubMed abstractSimilar articles


Edel A.
Genomic classifier can help identify patients who may not need adjuvant radiation.
Prostate Cancer InfoLink, Posted on
Article | Post abstract | Full-text PDF


Isbarn H, Giannarini G.
Re: Genomic Classifier Identifies Men with Adverse Pathology After Radical Prostatectomy Who Benefit from Adjuvant Radiation Therapy.
Eur Urol. 2015 Aug;68(2):337-8. doi: 10.1016/j.eururo.2015.03.014.
Article | PubMed abstract | Full-text PDF | Similar articles


Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E.
A genomic classifier to improve prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
2015 Genitourinary Cancers Symposium, J Clin Oncol 33, 2015 (suppl 7; abstr 154); 2015 Feb.
Article | Meeting abstract


Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E.
A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Eur Urol. 2015 Apr;67(4):778-86. doi: 10.1016/j.eururo.2014.10.036. Epub 2014 Nov 12.
Article | PubMed abstract | Similar articles


Lobo JM, Dicker AP, Buerki C, Daviconi E, Karnes RJ, Jenkins RB, Patel N, Den RB, Showalter TN.
Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.
PLoS One. 2015 Apr 2;10(3):e0116866. doi: 10.1371/journal.pone.0116866. eCollection 2015.
Article | PubMed abstract | Full-text PDF | Similar articles



Ross AE, D'Amico AV, Freedland SJ.
Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.
Prostate Cancer Prostatic Dis. 2015 Jun 30. doi: 10.1038/pcan.2015.31. [Epub ahead of print]
Article | PubMed abstract | Similar articles


Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM.
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Eur Urol. 2015 Jun 6. pii: S0302-2838(15)00444-3. doi: 10.1016/j.eururo.2015.05.042. [Epub ahead of print]
Article | PubMed abstract | Similar articles


Ross A, Michael Hiroshi Johnson, Kasra Yousefi, Elai Davicioni, Helen L. Fedor, Stephanie Glavaris, Voleak Choeurng, Christine Buerki, Lucia L.C. Lam, Nicholas Erho, Elizabeth B. Humphreys, George J. Netto, Misop Han, Alan W. Partin, Bruce J. Trock and Edward M. Schaeffer
Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort.
2015 ASCO Annual Meeting (May 29 - June 2, 2015). J Clin Oncol, Vol 33, No 15_suppl (May 20 Supplement), 2015: 5059
Article | Meeting abstract


Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM.
A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.
Prostate Cancer Prostatic Dis. 2014 Mar. doi: 10.1038/pcan.2013.49. Epub 2013 Oct 22.
Article | PubMed abstract | Full-text PDF | Related citations



Sedelaar JP, Schalken JA
The need for a personalized approach for prostate cancer management.
BMC Med. 2015 May 9;13:109. doi: 10.1186/s12916-015-0344-1.
Article | PubMed abstract | Full-text PDF | Similar articles


'Decipher' genomic test
Discovery and validation


Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB.
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.
PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013.
Article | PubMed abstract | Full-text PDF | Similar articles


Feng FY, Ghadessi M, Davicioni E, Crisan A, Erho N, Mitra AP, Triche TJ, Jenkins RB, Ross AE, Schaeffer EM.
Validation of a Genomic Classifier That Predicts Metastatic Disease Progression in Men With Biochemical Recurrence Post-Radical Prostatectomy

Int J Radiat Oncol Biol Phys, 2013 Oct 1, Vol. 87, Issue 2, Supplement, Page S125
Article | Journal abstract


Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB.
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.
J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017. Epub 2013 Jun 11.
Article | PubMed abstract | Full-text PDF | Similar articles



Ross A, Kasra Yousefi, Bruce J. Trock, Voleak Choeurng, Lucia L.C. Lam, Helen L. Fedor, Mercedeh Ghadessi, Christine Buerki, Stephanie Glavaris, Debasish Sundi, Jeffrey Tosoian, Misop Han, Elizabeth B. Humphreys, Alan W. Partin, George J. Netto, Elai Davicioni, Edward M. Schaeffer
Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise.
2015 Genitourinary Cancers Symposium, J Clin Oncol 33, 2015 (suppl 7; abstr 173); 2015 Feb.
Article | Meeting abstract


Ross AE, Mercedeh Ghadessi, Elai Davicioni, Anamaria Crisan, Christine Buerki, Nicholas Erho, Anirban Pradip Mitra, Darby J. S. Thompson, Timothy J. Triche, Edward M Schaeffer, Felix Yi-Chung Feng
Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.
2013 Genitourinary Cancers Symposium, J Clin Oncol 31, 2013 (suppl 6; abstr 52)
Article | Meeting abstract


'Decipher' genomic test
Molecular subtyping

Mills IG.
Molecular Subtyping of Prostate Cancer: A Partnership Model.
Eur Urol. 2015 May 19. pii: S0302-2838(15)00414-5. doi: 10.1016/j.eururo.2015.05.012. [Epub ahead of print]
Article | PubMed abstract | Similar articles


Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY.
Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes.
Eur Urol. 2015 May 8. pii: S0302-2838(15)00375-9. doi: 10.1016/j.eururo.2015.04.033. [Epub ahead of print]
Article | PubMed abstract | Similar articles


When is prostate cancer really cancer?

Berman DM, Epstein JI.
When is prostate cancer really cancer?
Urol Clin North Am. 2014 May;41(2):339-46. doi: 10.1016/j.ucl.2014.01.006. Epub 2014 Feb 21.
Article
| PubMed Abstract | Similar articles


Esserman LJ, Thompson IM Jr, Reid B.
Overdiagnosis and overtreatment in cancer: an opportunity for improvement.
JAMA. 2013 Aug 28;310(8):797-8.
Article | PubMed Abstract | Similar articles


Montironi R, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Santoni M, Briganti A, Montorsi F, Cheng L.
Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?
Diagn Pathol. 2014 Oct 18;9:190. doi: 10.1186/s13000-014-0190-z.
Article | PubMed Abstract | Full-text PDF | Similar articles


Nickel JC, Speakman M.
Should we really consider Gleason 6 prostate cancer?
BJU Int. 2012 Mar;109(5):645-6. doi: 10.1111/j.1464-410X.2011.10854.x. Epub 2011 Dec 22.
Article | PubMed Abstract | Full-text PDF | Similar articles



Soloway MS.
Re: overdiagnosis and overtreatment in cancer: an opportunity for improvement.
Eur Urol. 2014 Jan;65(1):249-50. doi: 10.1016/j.eururo.2013.10.023.
Article | PubMed Abstract | Full-text PDF | Similar articles

TREATMENT


Castration-resistant prostate cancer (CRPC)

Non-hormonal therapy
Radioligand therapy


Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, Gärtner F, Rogenhofer S, Schäfers M, Essler M.
Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.
EJNMMI Res. 2015 Dec;5(1):114. doi: 10.1186/s13550-015-0114-2. Epub 2015 Jun 20.
Article | PubMed abstract | Full-text PDF |
Similar articles


Bone targeted therapies / Painful bone metastases
Radium 223

El-Amm J, Aragon-Ching JB.
Radium-223 for the treatment of castration-resistant prostate cancer.
Onco Targets Ther. 2015 May 18;8:1103-9. doi: 10.2147/OTT.S44291. eCollection 2015.
Article | PubMed abstract | Full-text PDF |
Similar articles


Etchebehere E, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM.
Prognostic factors in patients treated with radium-223: the role of skeletal tumor burden on baseline 18F-fluoride-PET/CT in predicting overall survival.
J Nucl Med. 2015 Jun 11. pii: jnumed.115.158626. [Epub ahead of print]
Article | PubMed abstract | Similar articles


Lien LM, Tvedt B, Heinrich D.
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride.
Int J Urol Nurs. 2015 Mar;9(1):3-13. Published online 2014 Oct 14.
Article | PubMed abstract | Full-text PDF | Similar articles